Background: Large clinical studies assessing long-term adefovir dipivoxil salvage monotherapy in patients with lamivudine-resistant chronic hepatitis B (CHB) are lacking, particularly in patients positive for hepatitis B e antigen (HBeAg). We assessed the efficacy and resistance profile of adefovir dipivoxil monotherapy for up to 5 years in a large cohort of Korean patients with lamivudine-resistant CHB. Methods: A total of 320 patients (81.3% HBeAg-positive; 100% genotype C) with confirmed genotypic lamivudineresistant CHB were switched to adefovir dipivoxil 10 mg once daily. Liver function tests and HBV DNA were monitored every 3 months. Genotypic resistance to adefovir dipivoxil was performed in patients with detectable HBV DNA. Results: The overall cumulative virological response rate at 5 years of adefovir dipivoxil therapy was 48.8%. The virological response rate was significantly higher in HBeAgnegative patients (62.0% versus 45.9%; P=0.010). Most cases of virological response (131/134, 97.8%) occurred within the first 36 months of therapy. The 5-year cumulative probability of genotypic resistance and virological breakthrough was 65.6% and 61.8%, respectively. Predictive factors for a virological response included baseline HBeAg seronegativity, HBV DNA≤8 log 10 copies/ml and achievement of an on-treatment initial virological response. Conclusions: Adefovir dipivoxil salvage monotherapy for lamivudine-resistant CHB resulted in a modest cumulative virological response rate at 5 years, which was associated with progressive antiviral resistance. Consequently, adefovir monotherapy is not preferable as a first-line strategy for lamivudine resistance where combination lamivudine plus adefovir dipivoxil therapy is available.
Chronic HBV infection is an important public health problem that affects approximately 400 million people worldwide; it is a well-known risk factor for cirrhosis and hepatocellular carcinoma (HCC) [1] . Ongoing HBV replication with chronic inflammation is strongly associated with disease progression towards cirrhosis or HCC. Consequently, a primary goal of antiviral therapy is to potently and durably suppress serum HBV DNA levels [2, 3] .
Lamivudine (3TC) was one of the first nucleoside/ nucleotide analogues used to treat chronic hepatitis B (CHB). Treatment with 3TC has been clearly shown to significantly reduce the incidence of hepatic decompensation and risk of HCC [4] . However, 3TC is associated with the progressive development of genotypic resistance (up to 70% after 5 years) at the YMDD motif [5] ; thus, 3TC is no longer a preferred first-line antiviral agent.
Adefovir dipivoxil (ADV) was the second drug approved for treating CHB and has antiviral activity against both wild-type and 3TC-resistant HBV [6, 7] . Although switching to ADV monotherapy might be an effective salvage option for treating 3TC resistance [8] [9] [10] , subsequent studies have suggested that this strategy is associated with a suboptimal clinical course and increased risk of ADV resistance compared with combination ADV plus 3TC therapy [11] [12] [13] [14] . The ADV mutations at rtA181V/T and rtN236T appeared to emerge earlier and more frequently with ADV Introduction monotherapy, whereas combination ADV plus 3TC was unlikely to result in genotypic resistance to ADV [11] [12] [13] [14] . On the basis of these results, the combination of ADV and 3TC has gained more support in managing 3TC-resistant CHB. However, most studies with combination therapy in this clinical setting have examined Caucasian patients with predominantly hepatitis B virus e antigen (HBeAg)-negative infection. Furthermore, the maximum reported follow-up duration of salvage ADV monotherapy was only 3 years. Thus, further evaluation of ADV monotherapy in 3TC-resistant patients in different clinical cohorts and with a longer duration of follow-up would be of value.
Combination therapy in the setting of previous 3TC resistance is currently not applied universally, owing to higher costs. In Korea, where CHB is endemic, ADV monotherapy is a common salvage regimen as the result of a limited national insurance reimbursement scheme. The aim of this study was to assess the antiviral efficacy and resistance profile of long-term salvage ADV monotherapy in a large cohort of Korean patients with 3TC-resistant CHB, the majority of whom were HBeAg-positive.
Methods

Patients
Data were analysed for all patients who were switched to ADV because of 3TC resistance since October 2003. The inclusion criteria for this study were age >16 years, serum hepatitis B virus surface antigen present ≥6 months, serum HBV DNA≥10 5 copies/ml, therapy with 3TC for at least 6 months, HBV genotype C, confirmed mutation at the YMDD motif and follow-up for at least 1 year on ADV therapy. Exclusion criteria were decompensated liver cirrhosis (history of ascites, encephalopathy, varices, serum total bilirubin level >2.5 mg/dl, serum albumin <3 mg/dl or prothrombin time >3 s longer than normal), serum creatinine level >1.5 mg/dl, previous oral antiviral treatment other than 3TC, treatment with immunomodulatory drugs, current corticosteroid usage, coinfection with HCV and HDV or HIV, serious concurrent medical illness, evidence of HCC or prior organ transplantation.
Study design
Patients received oral ADV (10 mg once daily) after switching from 3TC with an overlap period of <2 months. Patients were monitored with laboratory assays at baseline and every 3 months. From July 2006, all patients commencing salvage ADV monotherapy had yearly prospective genotypic resistance testing. In addition, the stored samples that had been collected before July 2006 were tested for ADV-resistant mutations. The follow-up period was defined as the interval up to the last clinical visit or when virological breakthrough to ADV monotherapy was detected, whichever occurred first. This study was approved by the local institutional review board and conducted in accordance with the principles set forth in the Declaration of Helsinki.
Laboratory assays
Routine biochemical tests, including measurements of alanine aminotransferase (ALT), aspartate aminotransferase, total bilirubin, albumin, creatinine and prothrombin time were performed using a sequential multiple auto-analyser. HBeAg and antibodies against HBeAg were tested with enzyme-linked immunoassays (Dade Behring, Marburg, Germany). HBV DNA levels were quantified using a PCR assay on a COBAS TaqMan 48 analyser (Roche Molecular Systems, Branchburg, NJ, USA; lower detection limit 300 copies/ml). Genotypic resistance to 3TC or ADV was analysed using restriction fragment mass polymorphism (RFMP), as previously described [11, 12, [15] [16] [17] . Analytical sensitivities in detecting 3TC or ADV-resistant strains were estimated to be 300 copies/ml. The results of the RFMP assay were validated by 100% concordance with those obtained by repetitive direct sequencing.
End points and definitions
The primary end points of the study were the development of a virological response, virological breakthrough and genotypic resistance. A virological response was defined as an undetectable HBV DNA by PCR assay (<300 copies/ml) at any stage of therapy. Virological breakthrough was defined as an increase in HBV DNA≥1 log 10 copies/ml from the treatment nadir after an initial decrease of ≥2 log 10 copies/ml. Primary nonresponse was defined as a decrease in HBV DNA<2 log 10 copies/ml after 6 months of therapy [18] .
Secondary end points included biochemical response, initial virological response (IVR) and HBeAg seroconversion in HBeAg-positive patients. A biochemical response was defined as normalization of serum ALT; a biochemical breakthrough was defined as an increase of ALT≥ upper limit of normal (ULN; 49 IU/l) in conjunction with virological breakthrough after initial normalization [19] . An IVR was defined as HBV DNA<4 log 10 copies/ml after 6 months of treatment [20, 21] . Cirrhosis was defined based on ultrasonographic findings of a blunted, nodular liver edge accompanied by splenomegaly (>10 cm) with a low platelet count (<100 000/mm 3 ) [22, 23] .
Statistical analyses
Continuous variables were summarized as the median (range) or mean ±sd. Cumulative probabilities were estimated using Kaplan-Meier analysis; differences were tested using the log-rank test and multivariate analysis was performed using stepwise Cox regression analysis. A P-value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
The study included 320 patients with CHB who were switched to ADV monotherapy because of 3TC resistance ( Table 1 Table 2) . None of the patients in this study cleared hepatitis B surface antigen.
Genotypic resistance
The number of patients who had detectable HBV DNA at 1-5 years was 247, 234, 151, 63 and 25, respectively, and prospective yearly assessment of genotypic resistance was commenced in July 2006 among patients who had detectable HBV DNA. The cumulative probability of genotypic resistance to ADV was calculated to be 4.4%, 18.4%, 34.3%, 52.3% and 65.6% at 1-5 years, respectively. Higher rates of genotypic resistance were noted in HBeAg-positive patients than in HBeAg-negative patients through 5 years (71.4% versus 45.6%, P=0.028; Table 3 ). There was no difference in cumulative probability of genotypic resistance according to the types of YMDD motif mutation at baseline (P=0.339). Among 112 patients who had genotypic resistance to ADV, substitution at rtA181V was only detected in 50 (44.6%) patients, at rtA181T only in 29 (25.9%) patients, at rtA181V+T in 3 (2.7%), at rtN236T only in 8 (7.1%) and at both rtA181V/T and rtN236T in 22 (19.7%) patients.
Virological breakthrough
The cumulative probability of developing virological breakthrough at 1-5 years was 1.6%, 20.7%, 39.5%, 
Durability
ADV was stopped and durability could be evaluated in 13 patients: 8 were HBeAg-positive and 5 HBeAgnegative. These patients had received ADV therapy for over 1 year after either HBeAg seroconversion and/or undetectable HBV DNA. Six HBeAg-positive patients (75%) and one HBeAg-negative patient (20%) maintained sustained virological response over a 1 year period; however, the remaining patients demonstrated a virological rebound of >4 log 10 copies/ml within a 6 month period.
Prediction of virological response
Baseline HBeAg seronegativity (P=0.013), HBV DNA≤8 log 10 copies/ml (P=0.031) and on-treatment IVR (144/320 [45.0%]; P<0.001) were significant predictors of a virological response on univariate analysis. On multivariate analysis with baseline factors, HBeAg seronegativity remained significant (P=0.028), with a trend observed with HBV DNA≤8 log 10 (P=0.084). In HBeAg-positive patients, a significant difference in virological response was noted in patients with two favourable predictors (baseline HBV DNA≤8 log 10 copies/ml and achievement of IVR; 80/260 [30.8%]) versus those with either or none (180/260 [69.2%] P<0.001; Figure 2 ). The cumulative probability of a virological response in patients with both predictors was 38.7%, 57.6%, 65.4%, 74.4% and 74.4% at 1-5 years, respectively. Similarly, HBeAg-negative patients with both predictors had a significantly higher virological response (P=0.036), with a cumulative probability of 74.9% at month 60.
Prediction of virological breakthrough
Baseline predictors of virological breakthrough on both univariate and multivariate analysis included HBV DNA>8 log 10 copies/ml (P=0.014) and ALT level <2 ULN (P<0.001), which presumably resulted from the lack of immune response. HBeAg-positive patients with both baseline predictors had a significantly higher risk of virological breakthrough, with a cumulative probability of 2.8%, 26.3%, 50.7%, 62.6% and 73.5% in comparison to 0.0%, 17.2%, 17.2%, 29.7% and 41.4% in patients with either or none (P=0.001) at 1-5 years, respectively. A similar tendency was seen in HBeAg-negative patients showing virological breakthrough in 62.0% with both predictors versus 20.8% with either or none through month 60 (P=0.045).
Safety and clinical events
The majority of patients tolerated the drug well. The ADV dose was reduced to 10 mg on alternate days in 7 (2.2%) patients, because the serum creatinine increased to >0.5 mg/dl from baseline. In these patients, the serum creatinine level did not increase further after dose adjustment. No other significant adverse effects related to ADV were observed.
During ADV monotherapy, decompensated liver cirrhosis with ascites developed in 2 (1.0%) patients who had preserved liver function initially. Both patients were HBeAg-positive with continuous detectable HBV DNA despite ADV salvage monotherapy. In addition, 8 (2.5%) patients developed HCC; of these, 7 (87.5%) had cirrhosis and 5 (62.5%) had undetectable HBV DNA at the time of diagnosis of HCC. 
Discussion
This is the first study in a large cohort of Asian patients with 3TC-resistant CHB to assess the long-term efficacy of ADV switch monotherapy. All patients were Korean and had HBV genotype C infection. The overall cumulative virological response rate at month 60 was 48.8%. The long-term virological response rate was significantly higher in HBeAg-negative patients (62.0% versus 45.9%; P=0.010), which is consistent with previous integrated studies [14, 20, [24] [25] [26] [27] . Nevertheless, these results are inferior to previous studies with ADV plus 3TC combination therapy, which reported an undetectable HBV DNA in 82-100% of patients [14, 24, 27] .
ADV monotherapy was associated with a high and progressive risk of both virological breakthrough and genotypic resistance in this study, reaching up to 61.8% and 65.6% at year 5, respectively. This study is the first to provide 5-year genotypic resistance rates in which the data through year 2 are in accordance with previous studies reporting approximately 20% genotypic resistance [11, 12, 20, 28, 29] . Such high rates of resistance are discouraging compared with studies of ADV plus 3TC combination therapy in HBeAg-negative patients, where genotypic resistance is <4% at year 4 [14, 24, 26] . Although no conclusive long-term results of resistance profiles with ADV plus 3TC combination therapy have been reported in HBeAg-positive patients with 3TC-resistance, the rates of resistance in our study are also higher than those reported in studies evaluating salvage entecavir monotherapy, which reported a rate of 51% at year 5 [30, 31] . The higher rates of resistance with ADV might be attributable to its relatively lower degree of HBV DNA reduction [32] .
The predictors of achieving a virological response were evaluated in this study. In addition to HBeAg status, two additional factors were found to be significant: initial HBV DNA≤8 log 10 copies/ml and achievement of an IVR. When HBeAg-negative patients had both predictive factors, the virological response increased to 74.9% at month 60. Similarly, in HBeAg-positive patients, the virological response rate at month 60 in patients with both factors and with either or none was 74.4% versus 33.8%, respectively (P<0.001). Notably, long-term, large-scale data on ADV plus 3TC combination therapy in HBeAg-positive patients are scarce, except for a recent study by Yatsuji et al. [27] that reported a virological response of 68% through month 24 and 78% through month 36. Hence, ADV plus 3TC combination therapy also appears superior to ADV monotherapy in HBeAg-positive CHB. Consequently, salvage ADV monotherapy for 3TC resistance should not be considered a first-line therapy and, if necessary, should ideally be limited only to patients with favourable predictive factors in areas where medical resources are limited.
Interestingly, a virological response was achieved in most cases within the first 36 months of therapy, after which a plateau was observed. As described previously, of the 134 patients who achieved a virological response, 131 (97.8%) patients reached this through month 36. This suggests that little antiviral effect should be expected after 36 months. Similarly, few HBeAgpositive patients developed HBeAg seroconversion after month 36. By contrast, virological breakthrough increased linearly over time.
Limitations of this study were its mainly retrospective design and the fact that evaluation for genotypic resistance was only regularly performed after July 2006. A significant number of patients was excluded from analysis because of progressive virological breakthrough, resulting in a median follow-up duration of only 30 months and the relatively small number of patients over 4 years. The higher rate of genotypic resistance might be associated with the ultrasensitive RFMP method for detecting ADV-resistant mutations. The other potential limitation was that there was no ADV plus 3TC combination arm for direct comparison.
In summary, this study provides the first extensive, long-term, large-scale ADV monotherapy data in 3TC-resistant patients, especially in patients with HBeAgpositive CHB. The antiviral efficacy of ADV monotherapy was limited and expected mainly within the first 36 months. Predictive factors for antiviral efficacy included baseline HBeAg serostatus, HBV DNA≤8 log 10 copies/ml and achievement of an on-treatment IVR. The overall rates of virological breakthrough and genotypic resistance with ADV monotherapy were inferior to those obtained for the ADV plus 3TC combination reported in other studies. Therefore, ADV monotherapy should not be used as a first-line rescue therapy unless medical resources and cost are a major factor. Further investigation of response rates, resistance profiles and cost-effectiveness of ADV salvage monotherapy versus combination therapy is warranted in 3TC-resistant patients, particularly in those who are HBeAg-positive. These regimens should include newer and more potent drugs.
